Skip to main content
. Author manuscript; available in PMC: 2015 Feb 23.
Published in final edited form as: Breast Cancer Res Treat. 2014 Sep 2;147(3):473–485. doi: 10.1007/s10549-014-3082-8

Fig. 4.

Fig. 4

AR acts as a coactivator for ERα. Luciferase reporter assay showing in a ERα-transcriptional activity in AR OE cells compared to Arom3 cells after treatment with Ctrl (ethanol/DMSO), AD (10−8 M) ± Ana (10−6 M), in b ERα-transcriptional activity in AR Arom5 and AR Arom10 after treatment with AD (10−8 M) ± Cx (10−5 M), DHT (10−8 M) ± Cx (10−5 M). Data are representative of three independent experiments performed in triplicate. Columns mean, bars SD (**P < 0.01). c Proximity ligation assay showing AR-ERα complexes in cells after treatment with AD + Ana (10−8 and 10−6 M respectively). Red box shows a magnification of one representative area, yellow arrows point to AR-ERα complexes. d Quantitative chromatin immunoprecipitation (qChIP) assay showing AR and ERα enrichment on PSA enhancer region and pS2 promoter after treatment with AD (10−8 M) and DHT (10−8 M). AR and ERα enrichment on chromatin was quantified using qPCR and normalized to Ctrl. Data are representative of at least three independent experiments